The main product A400 (EP0031) of Colombotai Bio-B (06990.HK) was approved by the US Food and Drug Administration to begin phase 2 testing
Gelonghui, May 3 | Columbotai Bio-B (06990.HK) announced that the company's main product, A400 (EP0031) (rearrangement during transfection (RET) small molecule kinase inhibitor project, also known as KL590586 or EP0031), was approved by the US Food and Drug Administration (FDA) to enter phase 2 clinical development. A400 (EP0031) is a second-generation selective RET inhibitor (SRI) and has broad activity against common RET gene fusions and mutations. In March 2021, the company became an international drug development company headquartered in the United Kingdom
Chuangsheng Group-B (06628.HK) spent HK$91,000 to buy back 50,000 shares on May 3
Gelonghui May 3 | Chuangsheng Group-B (06628.HK) announced that it spent HK$91,000 to repurchase 50,000 shares on May 3.
Zhou Chunyan sold 380 million common shares of Imperial International Investment (00928.HK) off the market, worth approximately HK$12.617,700
On May 3, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 3, Zhou Chunyan sold $380 million ordinary shares of $Imperial International Investment (00928.HK) on April 29 at an average price of HK$0.0332 per share, worth approximately HK$12.617,700. After the sale, Zhou Chunyan's latest shareholding was 0 shares, and the good position ratio dropped from 20.54% to 0.00%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Listed public
Imperial International Investment (00928.HK) received an additional 380 million shares of common stock from Wei Yan, worth approximately HK$12.617,700
On May 3, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 3, Wei Yan increased her OTC share holdings of $Emperor International Investment (00928.HK) by $380 million at an average price of HK$0.0332 per share on April 29, worth about HK$12.617,700. After increasing her holdings, Wei Yan's latest shareholding was 380 million shares, and the good position ratio increased from 0.00% to 20.54%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. public
Imperial International Investment (00928.HK) received an additional 380 million shares of common shares worth approximately HK$126 million off the market by Wei Yan
On May 3, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 3, Wei Yan increased her OTC share holdings of $380 million of Imperial International Investment (00928.HK) shares at an average price of HK$0.332 per share on April 29, worth about HK$126 million. After increasing her holdings, Wei Yan's latest shareholding was 380 million shares, and the good position ratio increased from 0.00% to 20.54%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors of listed companies
Express News | Hong Kong stocks generally fell by “Pharmacology”. Pharmacovigilance fell by more than 10%. At one point, Yao Ming Biotech and Pharmaceutical Kangde fell by more than 7%.